| abstract |
The present invention relates to genetically modified pigs as models for studying psoriasis. The modified pig model expresses one or more phenotypes associated with psoriasis. Endogenous ILK-1Ra, JunB / cJun, CD18, IKK2 and / or LIG1 and / or modified pigs containing at least one mutation in the LIG1 gene and / or at least one human, pig and / or mouse PPAR, PPAR -δ, IκB-α, STAT3c, integrin β1, integrin α2, MEK1, amphiregulin, BMP-6, VEGF, JunBΔec-JunΔep, IL-1a, TGFβ1, CD18 hypo, Cre-IIKK2 fl7fl, Dsg1, SCCE, TGF-a, TNF-a, IL-20, IFN-g, LIG1 KO, KGF, IL-6, PAFR, Cre / Ikk2FL / FL, IL1R, Dsg3, IFN-γ, p40, IL1Ra Also disclosed are modified pigs comprising IKK2, JunB / c-Jun, and / or LIG1 genes, transcripts and / or translation products or portions thereof. The invention further discloses methods for producing modified pigs, methods for assessing response in therapeutic treatment of psoriasis, methods for screening the effectiveness of pharmaceutical compositions, and methods for treating humans suffering from psoriasis. |